{
    "hands_on_practices": [
        {
            "introduction": "The central goal of exon skipping therapy is to restore the translational reading frame disrupted by a pathogenic mutation. This restoration relies on a fundamental mathematical principle derived from the triplet nature of the genetic code. This exercise  provides a hands-on opportunity to apply this core concept by calculating whether a proposed therapeutic skip can correct an out-of-frame deletion, turning a complex genetic problem into a straightforward arithmetic check.",
            "id": "5029276",
            "problem": "A male patient with Duchenne Muscular Dystrophy (DMD) has a pathogenic deletion within the dystrophin gene that removes $D = 229$ coding nucleotides from the mature messenger ribonucleic acid (mRNA) coding sequence. An antisense oligonucleotide (ASO) therapy is proposed to skip exon $E$, which has a coding length of $L_E = 158$ nucleotides, in order to potentially restore the open reading frame. Starting from the Central Dogma and the codon triplet rule that translation proceeds in codons of $3$ nucleotides, justify the criterion for whether the reading frame is restored when a second deletion (exon skipping) is introduced, and then compute the quantity $r$, defined as the remainder when the net coding nucleotide shift from the combined deletions is divided by $3$. Report $r$ as an integer in $\\{0,1,2\\}$. No rounding is required. The answer must be a single number.",
            "solution": "The problem statement is evaluated as scientifically grounded, well-posed, objective, and complete. It is based on established principles of molecular genetics and poses a solvable question with all necessary data provided. Therefore, a solution will be provided.\n\nThe core principle for solving this problem is the triplet nature of the genetic code in the process of translation. According to the Central Dogma of molecular biology, the genetic information encoded in deoxyribonucleic acid (DNA) is transcribed into messenger ribonucleic acid (mRNA), which is then translated into a protein. During translation, the ribosome reads the mRNA sequence in contiguous, non-overlapping sets of three nucleotides, known as codons. This establishes a specific \"reading frame\".\n\nA frameshift mutation occurs when the number of inserted or deleted nucleotides in the coding sequence is not an integer multiple of $3$. Such a mutation alters the grouping of nucleotides into codons from the point of the mutation downstream, leading to a completely different amino acid sequence and typically the premature introduction of a stop codon. This results in a truncated and non-functional protein. Duchenne Muscular Dystrophy (DMD) is often caused by such out-of-frame deletions in the dystrophin gene.\n\nThe criterion for restoring the reading frame is to ensure that the total number of deleted nucleotides from the coding sequence is a multiple of $3$. If the net number of removed nucleotides is divisible by $3$, the downstream reading frame remains intact, although some amino acids will be missing. This often results in an internally truncated but partially functional protein, which can convert a severe phenotype like DMD into a milder one, such as Becker Muscular Dystrophy (BMD).\n\nLet $N$ be the number of nucleotides in a deletion. The deletion is \"in-frame\" if $N \\equiv 0 \\pmod{3}$, and \"out-of-frame\" if $N \\equiv 1 \\pmod{3}$ or $N \\equiv 2 \\pmod{3}$.\n\nThe problem states an initial pathogenic deletion of $D = 229$ coding nucleotides. We can determine the effect of this deletion on the reading frame by calculating its size modulo $3$:\n$$D \\pmod{3} = 229 \\pmod{3}$$\nThe sum of the digits of $229$ is $2+2+9 = 13$. Since $13 \\pmod{3} = 1$, we have:\n$$229 \\equiv 1 \\pmod{3}$$\nThis is an out-of-frame deletion, which is consistent with a severe DMD phenotype.\n\nThe proposed therapy involves skipping exon $E$, which has a coding length of $L_E = 158$ nucleotides. This constitutes a second, therapeutic deletion. The effect of this second deletion on the reading frame, considered in isolation, is:\n$$L_E \\pmod{3} = 158 \\pmod{3}$$\nThe sum of the digits of $158$ is $1+5+8 = 14$. Since $14 \\pmod{3} = 2$, we have:\n$$158 \\equiv 2 \\pmod{3}$$\n\nThe goal is to determine if the combination of these two deletions restores the open reading frame. This requires calculating the total number of deleted nucleotides, $N_{\\text{total}}$, and checking if it is divisible by $3$.\n$$N_{\\text{total}} = D + L_E$$\nSubstituting the given values:\n$$N_{\\text{total}} = 229 + 158 = 387$$\n\nThe problem asks for the quantity $r$, defined as the remainder when the net coding nucleotide shift is divided by $3$. This is equivalent to calculating $N_{\\text{total}} \\pmod{3}$.\n$$r = N_{\\text{total}} \\pmod{3} = 387 \\pmod{3}$$\nTo calculate this, we can sum the digits of $387$:\n$$3 + 8 + 7 = 18$$\nSince $18$ is divisible by $3$ ($18 = 6 \\times 3$), the number $387$ is also divisible by $3$. Therefore, the remainder is $0$.\n$$r = 387 \\pmod{3} = 0$$\n\nAlternatively, using the remainders of the individual deletions:\n$$r = (D + L_E) \\pmod{3} = (D \\pmod{3} + L_E \\pmod{3}) \\pmod{3}$$\n$$r = (1 + 2) \\pmod{3} = 3 \\pmod{3} = 0$$\nBoth methods yield the same result. A remainder of $r = 0$ signifies that the net deletion of $387$ nucleotides is a multiple of $3$. This restores the reading frame downstream of the deleted segments, making the therapeutic strategy viable in principle. The requested quantity $r$ is $0$.",
            "answer": "$$\\boxed{0}$$"
        },
        {
            "introduction": "Building a successful therapy involves much more than the basic frame-restoration calculation. Designing an effective antisense oligonucleotide (AON) is a multi-step process that requires integrating principles from bioinformatics, biophysics, and molecular biology to ensure the drug is potent, specific, and safe. This problem  challenges you to think like a therapeutic designer, asking you to evaluate and select a comprehensive, rational pipeline for creating a new AON from first principles.",
            "id": "5029328",
            "problem": "A research team aims to design an antisense oligonucleotide (AON) to induce skipping of exon $51$ in the Duchenne muscular dystrophy (DMD) pre-messenger ribonucleic acid (pre-mRNA), restoring the reading frame in affected dystrophin transcripts. From first principles, the design must follow the Central Dogma (deoxyribonucleic acid to ribonucleic acid to protein), the mechanism of spliceosome-mediated splicing, and sequence-specific hybridization thermodynamics. The team is considering several pipelines. Which option most accurately outlines a scientifically sound pipeline that integrates motif mapping, secondary structure prediction, off-target hybridization screening, and synthesis constraints for an AON targeting exon $51$?\n\nA. Begin with the DMD pre-mRNA sequence covering exon $51$ and its flanking intronic regions expressed in skeletal muscle; map canonical splicing features (the $5'$ splice site, $3'$ splice site, branch point, and polypyrimidine tract) and exonic splicing enhancer (ESE) and exonic splicing silencer (ESS) motifs using position weight matrices; select candidate AON target windows that mask ESE clusters and/or splice site-proximal elements to reduce exon recognition; evaluate local pre-mRNA accessibility by predicting minimum free energy structures and base-pairing probabilities to prioritize unpaired regions; estimate binding strength using hybridization thermodynamics (Gibbs free energy, $\\Delta G$, and melting temperature, $T_m$) under physiological ionic conditions (e.g., sodium ion concentration near $0.15$ molar), aiming for on-target duplexes with $T_m$ exceeding $37^\\circ \\mathrm{C}$ by roughly $10$ to $20^\\circ \\mathrm{C}$; perform transcriptome-wide off-target screening to exclude candidates with long contiguous complementarity (e.g., $>15$ nucleotides) or predicted off-target duplex $T_m$ within $\\sim 5$ to $10^\\circ \\mathrm{C}$ of the on-target; finalize AON designs of length $\\sim 20$ to $30$ nucleotides with guanine-cytosine content $\\sim 40\\%$ to $60\\%$, avoiding homopolymer runs and immunostimulatory motifs, minimizing self-complementarity (hairpins and dimers with unfavorable $\\Delta G$), and selecting steric-block chemistries such as phosphorodiamidate morpholino oligomer (PMO) or $2'$-O-methyl phosphorothioate, followed by synthesis feasibility checks.\n\nB. Start from dystrophin protein domain architecture to identify the rod domain around where exon $51$ would encode; design peptide mimetics to interfere with translation of the exon $51$ segment; model deoxyribonucleic acid supercoiling and nucleosome positioning over the exon $51$ locus to predict accessibility; perform Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) off-target cleavage scoring; synthesize unmodified phosphodiester deoxyribonucleic acid oligonucleotides as AONs with high guanine-cytosine content to maximize stability, skipping computational ribonucleic acid secondary structure and hybridization assessments.\n\nC. Use microRNA-like design rules to select a $7$-nucleotide seed targeting the $3'$ untranslated region of DMD; extend to a $21$-nucleotide duplex and predict Argonaute loading; perform genome-wide microRNA off-target searching focused on $3'$ untranslated regions; favor palindromic sequences to enhance stability; synthesize small interfering ribonucleic acid (siRNA) duplexes and deliver them to muscle, assuming reduced expression of dystrophin will promote exon $51$ skipping.\n\nD. Choose codon-optimized segments within the exon $51$ coding sequence based on deoxyribonucleic acid or complementary deoxyribonucleic acid sequences; select the highest guanine-cytosine content to ensure strong binding; use basic sequence alignment to the genome to exclude perfect matches elsewhere; omit explicit mapping of splice regulatory elements and omit ribonucleic acid secondary structure prediction; select standard phosphodiester chemistry for ease of synthesis.\n\nE. Design an AON that self-anneals strongly to form a stable hairpin (highly negative $\\Delta G$) to prevent degradation; prioritize internal palindromic repeats and homopolymeric runs to simplify synthesis; ignore splicing regulatory motifs and off-target hybridization, under the assumption that any stable oligonucleotide will bind the target pre-messenger ribonucleic acid effectively.\n\nChoose the single best option.",
            "solution": "### Problem Validation\n\n**Step 1: Extract Givens**\n- **Goal**: Design an antisense oligonucleotide (AON) to induce skipping of exon $51$ in the Duchenne muscular dystrophy (DMD) pre-messenger ribonucleic acid (pre-mRNA).\n- **Intended Outcome**: Restore the reading frame in dystrophin transcripts.\n- **Governing Principles**: Central Dogma, spliceosome-mediated splicing, sequence-specific hybridization thermodynamics.\n- **Task**: Identify the most scientifically sound pipeline that integrates (1) motif mapping, (2) secondary structure prediction, (3) off-target hybridization screening, and (4) synthesis constraints for an AON targeting exon $51$.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientific Grounding**: The problem is correctly framed within established principles of molecular biology, genetics, and bioinformatics. The concepts of DMD, exon skipping, pre-mRNA splicing, and the biophysical principles of nucleic acid hybridization are all scientifically valid.\n- **Well-Posedness**: The problem asks for the identification of the \"most accurately\" described scientific pipeline from a set of options, which is a standard, well-posed comparative assessment task.\n- **Objectivity**: The problem statement uses precise, technical language and is free of subjective terminology.\n\n**Step 3: Verdict and Action**\nThe problem statement is valid. A solution will be derived by evaluating the provided options against first principles of therapeutic oligonucleotide design.\n\n### Solution Derivation\n\nThe design of an AON for therapeutic exon skipping is a multi-parameter optimization problem. A scientifically sound pipeline must systematically address target selection, accessibility, binding affinity, specificity, and chemical stability.\n\n**Option-by-Option Analysis**\n\n**A.** This option provides a comprehensive and accurate description of the state-of-the-art pipeline for AON design. It correctly sequences the process from target identification (mapping splicing motifs like ESEs), accessibility analysis (RNA secondary structure), biophysical optimization (thermodynamics, $T_m$), and safety checks (off-target screening), to final design heuristics and selection of appropriate steric-blocking chemistries (PMO, $2'$-O-Me). This represents a complete and rational design strategy. **Verdict: Correct.**\n\n**B.** This option is fundamentally flawed. It confuses the therapeutic target (proposing interference with protein translation instead of pre-mRNA splicing), the relevant biological process (modeling DNA supercoiling instead of RNA splicing), and the therapeutic modality (mentioning CRISPR, a DNA-editing tool). **Verdict: Incorrect.**\n\n**C.** This option incorrectly describes the RNA interference (RNAi) pathway, which typically aims to degrade mRNA or repress translationâ€”the opposite of the therapeutic goal. The mechanism (siRNA, Argonaute) and target ($3'$ UTR) are inappropriate for exon skipping. **Verdict: Incorrect.**\n\n**D.** This option represents a naive and incomplete approach. It omits critical steps like mapping splicing regulatory elements and predicting RNA structure. It also specifies a chemically unstable phosphodiester backbone that would be rapidly degraded in vivo. **Verdict: Incorrect.**\n\n**E.** This option's logic is inverted. It advocates for designing an AON that self-anneals strongly (highly negative $\\Delta G$), which would prevent it from binding to its intended target. Ignoring splicing motifs and off-target analysis is antithetical to rational drug design. **Verdict: Incorrect.**\n\n**Conclusion**\nOption A is the only choice that outlines a complete, logically sequential, and scientifically valid pipeline for the rational design of a therapeutic AON for exon skipping. It correctly integrates all the required components from target analysis to chemical synthesis considerations.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "After a therapy is designed and administered, the critical work of evaluating its effectiveness begins, and the results are often not as simple as expected. A common challenge in clinical trials is observing a discrepancy between the amount of corrected messenger ribonucleic acid (mRNA) and the actual amount of functional protein produced in the patient's cells. This advanced problem  places you in the role of a clinical scientist, tasked with explaining such a discordance by considering a range of technical and biological factors, from assay limitations to the complexities of protein stability.",
            "id": "5029348",
            "problem": "A male patient with Duchenne muscular dystrophy undergoing antisense oligonucleotide (ASO) exon skipping therapy has a post-treatment vastus lateralis biopsy at week $24$. Reverse transcription polymerase chain reaction (RT-PCR) across the targeted exon junction shows that the exon-skipped dystrophin messenger ribonucleic acid (mRNA) constitutes $30\\%$ of total dystrophin mRNA species detected in bulk muscle homogenate. A Western blot (WB) quantified against a pooled normal control, normalized to spectrin, shows dystrophin protein at $5\\%$ of normal. Using the Central Dogma (deoxyribonucleic acid to ribonucleic acid to protein) and the core definitions of pre-mRNA splicing, translation, and protein turnover, which of the following explanations and follow-up assay plans best account for the discordance between the RT-PCR and Western blot results? Select ALL that apply.\n\nA. Skipped transcript quantification may be biased by primer/probe efficiency, and the WB antibody epitope may be partially deleted by the therapeutic exon skip (epitope masking), artificially inflating the $30\\%$ mRNA estimate and deflating the $5\\%$ protein estimate. Follow-up: droplet digital polymerase chain reaction (ddPCR) with multiple junction-spanning assays to cross-validate the skipped fraction, long-read RNA sequencing to detect cryptic splice events, and protein quantification with multiple dystrophin antibodies recognizing distinct epitopes plus targeted mass spectrometry; add dystrophin immunofluorescence (IF) to assess sarcolemmal localization.\n\nB. The $30\\%$ RT-PCR value reflects a fraction among dystrophin transcripts, not their absolute abundance in the biopsy; extensive fibrosis/fat replacement and mosaic fiber rescue can yield low absolute dystrophin while a minority of treated myofibers contribute a high skipped fraction. Follow-up: IF on transverse sections co-stained for dystrophin and a sarcolemmal marker (for example, spectrin) to quantify fiber-level rescue and patchiness, histopathology to estimate muscle content versus fibrosis/fat, and absolute mRNA quantification (for example, ddPCR normalized to stable housekeeping transcripts) and laser capture microdissection to link fiber-level RNA and protein.\n\nC. The truncated, in-frame dystrophin isoform produced by exon skipping may have reduced stability or improper assembly into the dystrophin-associated glycoprotein complex (DGC), resulting in rapid degradation and low steady-state protein despite adequate mRNA. Follow-up: cycloheximide chase to measure dystrophin half-life, proteasome inhibition assays, and co-immunoprecipitation (co-IP) of dystrophin with DGC components to test complex assembly, together with membrane versus cytosolic fractionation to evaluate mislocalization.\n\nD. Nonsense-mediated decay (NMD) selectively targets the exon-skipped isoform, preventing its translation, thereby explaining the low protein despite $30\\%$ skipped mRNA. Follow-up: inhibit translation (for example, emetine) to block NMD and look for increased skipped transcript abundance as confirmation.\n\nE. Western blot quantification is artifactually low because dystrophin is a soluble cytosolic protein that is lost during membrane fractionation; measuring circulating dystrophin in serum would better reflect treatment effect.",
            "solution": "### Problem Validation\n\nThe problem presents a realistic and well-defined scenario from clinical drug development for Duchenne muscular dystrophy (DMD): a quantitative discrepancy between a messenger ribonucleic acid (mRNA) biomarker and a protein biomarker following therapy. The question asks for plausible scientific explanations for the discordance ($30\\%$ skipped mRNA vs. $5\\%$ total protein). The problem is scientifically grounded, well-posed, and objective. A solution will be derived by analyzing each option based on principles of molecular biology, biochemistry, and the technical limitations of common laboratory assays.\n\n### Solution Derivation\n\nThe discrepancy between mRNA and protein levels can arise from three main categories of factors: (1) technical or assay-related artifacts, (2) biological tissue-level heterogeneity, and (3) biological transcript/protein-level effects such as translation efficiency and protein stability.\n\n**Option-by-Option Analysis**\n\n**A.** This option proposes plausible **technical artifacts**. RT-PCR results can be biased by primer efficiency, potentially overestimating the mRNA level. More importantly, if the Western blot antibody's binding site (epitope) is located on the protein segment encoded by the skipped exon, the antibody will fail to detect the new, shorter protein, leading to a severe underestimation of its quantity. The proposed follow-up plan (using ddPCR, multiple antibodies, and mass spectrometry) is a state-of-the-art approach to rule out these assay-specific issues. **Verdict: Correct.**\n\n**B.** This option proposes a crucial **biological explanation at the tissue level**. DMD muscle contains significant non-muscle tissue (fibrosis, fat), and ASO delivery is often \"mosaic,\" meaning some fibers are treated effectively while others are not. A bulk homogenate measurement averages these effects. It is plausible that a small population of highly corrected fibers produces the $30\\%$ relative mRNA figure, but this translates to only $5\\%$ protein when averaged across the entire heterogeneous tissue sample. The follow-up plan (immunofluorescence for mosaicism, histopathology for tissue composition) is the correct way to investigate this. **Verdict: Correct.**\n\n**C.** This option addresses a plausible **post-translational biological mechanism**. The new, truncated dystrophin protein, while in-frame, may not fold as stably or assemble correctly into its protein complex at the cell membrane. This could lead to its rapid degradation, resulting in low steady-state protein levels despite adequate mRNA production. The proposed experiments (cycloheximide chase for protein half-life, co-immunoprecipitation for complex assembly) are the standard methods to test this hypothesis. **Verdict: Correct.**\n\n**D.** This option's premise is **fundamentally flawed**. The entire purpose of therapeutic exon skipping in DMD is to restore the translational reading frame to *avoid* triggering Nonsense-Mediated Decay (NMD). NMD targets the original, uncorrected, out-of-frame transcripts, *not* the therapeutically corrected in-frame ones. Thus, NMD cannot be the cause of low protein yield from the skipped mRNA. **Verdict: Incorrect.**\n\n**E.** This option is based on **major factual errors** about dystrophin biology. Dystrophin is a large, membrane-associated structural protein, not a soluble cytosolic protein. Its presence in serum is a marker of muscle damage, not a measure of therapeutic production. **Verdict: Incorrect.**\n\n**Conclusion**\nOptions A, B, and C each provide a scientifically valid and distinct explanation for the observed mRNA-protein discordance, covering technical artifacts, tissue heterogeneity, and protein biochemistry, respectively.",
            "answer": "$$\\boxed{ABC}$$"
        }
    ]
}